Marshall Wace LLP Takes $409,000 Position in Immatics (NASDAQ:IMTX)

Marshall Wace LLP purchased a new position in Immatics (NASDAQ:IMTX - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 57,487 shares of the company's stock, valued at approximately $409,000.

Other hedge funds have also recently modified their holdings of the company. Guggenheim Capital LLC bought a new stake in Immatics during the fourth quarter valued at about $101,000. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in Immatics by 24.6% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 22,701 shares of the company's stock worth $163,000 after acquiring an additional 4,477 shares in the last quarter. Aristides Capital LLC bought a new stake in Immatics during the 4th quarter worth approximately $205,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Immatics in the fourth quarter worth $211,000. Finally, Platinum Investment Management Ltd. increased its stake in Immatics by 53.1% in the 4th quarter. Platinum Investment Management Ltd. now owns 311,722 shares of the company's stock worth $2,216,000 after buying an additional 108,108 shares in the last quarter. Institutional investors own 64.41% of the company's stock.

Immatics Price Performance

Shares of NASDAQ:IMTX traded up $0.04 during trading hours on Friday, hitting $4.38. 149,071 shares of the company's stock traded hands, compared to its average volume of 657,607. The business has a fifty day moving average price of $4.48 and a 200-day moving average price of $6.07. Immatics has a 1 year low of $3.30 and a 1 year high of $13.77. The firm has a market capitalization of $532.39 million, a P/E ratio of -6.64 and a beta of 0.87.

Immatics (NASDAQ:IMTX - Get Free Report) last issued its earnings results on Thursday, March 27th. The company reported $0.48 EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.51. The business had revenue of $15.67 million for the quarter, compared to the consensus estimate of $16.16 million. Immatics had a negative net margin of 47.94% and a negative return on equity of 15.90%. As a group, equities analysts predict that Immatics will post -0.72 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reissued an "overweight" rating on shares of Immatics in a report on Tuesday, April 1st. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $16.67.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.